Literature DB >> 20659803

In vitro ADMET and physicochemical investigations of poly-N-methylated peptides designed to inhibit Abeta aggregation.

Partha Pratim Bose1, Urmimala Chatterjee, Ina Hubatsch, Per Artursson, Thavendran Govender, Hendrik G Kruger, Margareta Bergh, Jan Johansson, Per I Arvidsson.   

Abstract

N-Methylation is a common strategy for improving oral bioavailability of peptide-based lead structures. Herein, we present a detailed study on how the degree of N-methylation affects the absorption-distribution-metabolism-excretion-toxicity (ADMET) properties such as solubility, membrane transport, proteolytic stability, and general cell toxicity of the investigated peptides. As representative structures we chose hexapeptides 1-8. These peptides, corresponding to N-methylated analogues of residues 16-21 and 32-37 of the Abeta-peptide, pathological hallmark of Alzheimer's disease (AD), have previously been shown to inhibit aggregation of Abeta fibrils in vitro. This study suggests that poly-N-methylated peptides are non-toxic and have enhanced proteolytic stability over their non-methylated analogues. Furthermore, solubility in aqueous solution is seen to increase with increased degree of N-methylation, while membrane transport was found to be low for all investigated hexapeptides. The present results, together with those reported in the literature, suggest that poly-N-methylated peptides, especially shorter or equal to six residues, can be suitable candidates for drug design. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20659803     DOI: 10.1016/j.bmc.2010.06.087

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  4 in total

1.  Prediction and interpretation of the lipophilicity of small peptides.

Authors:  Alessia Visconti; Giuseppe Ermondi; Giulia Caron; Roberto Esposito
Journal:  J Comput Aided Mol Des       Date:  2015-01-11       Impact factor: 3.686

Review 2.  Modulation of Amyloid β-Protein (Aβ) Assembly by Homologous C-Terminal Fragments as a Strategy for Inhibiting Aβ Toxicity.

Authors:  Huiyuan Li; Farid Rahimi; Gal Bitan
Journal:  ACS Chem Neurosci       Date:  2016-07-05       Impact factor: 4.418

Review 3.  Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.

Authors:  Dimitrios C Mastellos; Despina Yancopoulou; Petros Kokkinos; Markus Huber-Lang; George Hajishengallis; Ali R Biglarnia; Florea Lupu; Bo Nilsson; Antonio M Risitano; Daniel Ricklin; John D Lambris
Journal:  Eur J Clin Invest       Date:  2015-03-09       Impact factor: 4.686

4.  New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties.

Authors:  Hongchang Qu; Daniel Ricklin; Hongjun Bai; Hui Chen; Edimara S Reis; Mateusz Maciejewski; Apostolia Tzekou; Robert A DeAngelis; Ranillo R G Resuello; Florea Lupu; Paul N Barlow; John D Lambris
Journal:  Immunobiology       Date:  2012-06-17       Impact factor: 3.144

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.